EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial
benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare
the anti-tumor effects of EP-100 combined with weekly paclitaxel versus paclitaxel alone in
patients with ovarian cancer. Secondary Objectives: o Randomized Phase: Quantify any
significant changes in the safety profile of weekly paclitaxel alone compared to the doublet
combination of paclitaxel with EP-100. o Determine an initial benefit/risk profile for this
new drug combination.